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Abstract
BACKGROUND—Patients with relapsed chronic lymphocytic leukemia (CLL) who have
clinically significant coexisting medical conditions are less able to undergo standard chemo-
therapy. Effective therapies with acceptable side-effect profiles are needed for this patient
population.
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METHODS—In this multicenter, randomized, double-blind, placebo-controlled, phase 3 study,
we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta iso-form of
phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo. We
randomly assigned 220 patients with decreased renal function, previous therapy-induced
myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a
dose of 150 mg) or placebo twice daily. The primary end point was progression-free survival. At
the first prespecified interim analysis, the study was stopped early on the recommendation of the
data and safety monitoring board owing to overwhelming efficacy.
RESULTS—The median progression-free survival was 5.5 months in the placebo group and was
not reached in the idelalisib group (hazard ratio for progression or death in the idelalisib group,
0.15; P<0.001). Patients receiving idelalisib versus those receiving placebo had improved rates of
overall response (81% vs. 13%; odds ratio, 29.92; P<0.001) and overall survival at 12 months
(92% vs. 80%; hazard ratio for death, 0.28; P = 0.02). Serious adverse events occurred in 40% of
the patients receiving idelalisib and rituximab and in 35% of those receiving placebo and
rituximab.
CONCLUSIONS—The combination of idelalisib and rituximab, as compared with placebo and
rituximab, significantly improved progression-free survival, response rate, and overall survival
among patients with relapsed CLL who were less able to undergo chemo-therapy. (Funded by
Gilead; ClinicalTrials.gov number, NCT01539512.)
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia among adults.
Standard treatments include combinations of purine analogues, alkylating agents, and
monoclonal antibodies. In younger patients without major coexisting illnesses, these
regimens can provide high response rates of durable length but have substantial toxic
effects. As a result, these treatments often have unacceptable side effects in older patients
and those with coexisting illnesses.1
Patients with relapsed CLL often have limited options because of the development of
resistance to, or persisting toxic effects of, previous therapies. This is particularly true for
elderly patients and those with coexisting illnesses.2 For these patients, the guidelines of the
National Comprehensive Cancer Network recognize rituximab (Rituxan, Genentech/Biogen
Idec) as a treatment option.3 Rituximab is commonly used in such patients, although it has
not been approved as monotherapy. Rates of response to rituximab vary, and the duration of
progression-free survival is generally short.4-7
The B-cell–receptor signaling pathway plays a key role in the pathogenesis of CLL.8-11
Signaling through the B-cell receptor is mediated in part by the activation of the delta
isoform of phosphatidylinositol 3-kinase (PI3Kδ). The delta iso-form is one of four catalytic
isoforms (p110 α, β, γ, and δ) that differ in their tissue expression, with PI3Kδ being highly
expressed in lymphoid cells12 and the most critical isoform involved in the malignant
phenotype in CLL.13 It activates the serine–threonine kinases AKT and mammalian target of
rapamycin (mTOR) and exerts pleiotropic effects on cell metabolism, migration,
proliferation, survival, and differentiation.14,15 Additional surface receptors that may play
important roles in CLL pathophysiology (e.g., CXCR4,16 CD40,17 and CD49d18) also
transduce their signals in part through PI3Kδ.
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Idelalisib (formerly called GS-1101 and CAL-101) is a potent, oral, selective small-
molecule inhibitor of PI3Kδ.15 In phase 1 studies, idelalisib (both as a single agent and in
combination with other agents, including rituximab19,20) had clinically significant activity
with an acceptable toxicity profile in patients with relapsed or refractory CLL. On the basis
of these encouraging results, we conducted Study 116 — a phase 3, randomized, double-
blind, placebo-controlled trial of combination therapy with idelalisib and rituximab in
patients with relapsed CLL.
METHODS
STUDY DESIGN AND CONDUCT
The trial was designed by the sponsor, Gilead, with input from all the authors. Gilead
implemented the study and provided data analysis. The trial was conducted, according to the
principles of Good Clinical Practice, at 90 centers in the United States and Europe after
approval by the relevant regulatory authorities and the institutional review board at each
study site. All patients provided written informed consent. All the authors had full access to
the study data and were involved in the interpretation of the data and in the preparation,
revision, and final approval of the manuscript. All the authors made the decision to submit
the manuscript for publication and vouch for the accuracy and completeness of the data and
adherence to the study protocol (available with the full text of this article at NEJM.org).
STUDY TREATMENT
All patients were assigned to receive rituximab intravenously (at a dose of 375 mg per
square meter of body-surface area), followed by 500 mg per square meter every 2 weeks for
4 doses and then every 4 weeks for 3 doses, for a total of 8 infusions. Patients were stratified
according to the presence of 17p deletion (a deletion of the 17p13 chromosomal region in
the gene encoding tumor-suppressor p53 [TP53]) or other TP53 mutations or the lack of
somatic hypermutation in the gene encoding the immunoglobulin heavy-chain variable
region (IGHV), all of which are associated with an inferior outcome. The patients were then
randomly assigned to receive rituximab with either oral idelalisib (at a dose of 150 mg)
(idelalisib group) or placebo (placebo group) twice a day.
Patients in the placebo group who had disease progression while enrolled in Study 116 could
enroll in Study 117 to receive idelalisib. Patients in the idelalisib group who had disease
progression could receive an increased dose of the drug (300 mg twice daily).
ELIGIBILITY
Eligible patients had CLL that had progressed within 24 months after their last treatment and
were not able to receive cytotoxic agents for one or more of the following reasons: severe
neutropenia or thrombocytopenia caused by cumulative myelotoxicity from previous
therapies, an estimated creatinine clearance of less than 60 ml per minute, or a score on the
Cumulative Illness Rating Scale (CIRS)21 of more than 6 for coexisting illnesses not related
to CLL.2 (The CIRS score ranges from 0 to 56, with higher scores indicating an increased
number or greater severity of coexisting illnesses.) Previous treatment must have included
either a CD20 antibody– based regimen or at least two previous cytotoxic regimens.
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ASSESSMENTS
We scheduled clinic visits, which included laboratory testing, every 2 weeks for the first 12
weeks, then every 4 weeks for 12 weeks, and then every 6 weeks for 24 weeks, followed by
visits every 12 weeks. The treatment response was assessed on the basis of serial computed
tomography or magnetic resonance imaging of the neck, chest, abdomen, and pelvis
(performed every 8 weeks for 6 months and every 12 weeks thereafter) and laboratory
hematologic measurements.
We used the criteria of the International Workshop on Chronic Lymphocytic Leukemia
(IWCLL)22 to determine rates of response and progression, including Richter's
transformation (in which CLL is transformed into an aggressive lymphoma). These criteria
were recently modified to exclude lymphocytosis as an isolated criterion for disease
progression in patients treated with agents inhibiting the B-cell receptor.23,24 Independent
review by a committee whose members were unaware of study-group assignments
determined rates of response and disease progression for each patient and the dates of
occurrence.
Centralized reference diagnostic procedures were performed at Ulm University (Ulm,
Germany) or Cancer Genetics (Rutherford, NJ) with the use of fluorescence in situ
hybridization for genomic aberrations, DNA sequencing for IGHV mutation status, and
WAVE DNA fragment analysis and confirmatory Sanger sequencing for TP53 analyses, as
described previously.25-27 Adverse events were graded with the use of the National Cancer
Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
END POINTS
The primary end point of the trial was progression-free survival. Secondary end points were
rates of overall and complete response, lymph-node response, and overall survival.
STATISTICAL ANALYSIS
We calculated progression-free survival, which was defined as the interval from
randomization to disease progression or death from any cause (whichever came first), using
the Kaplan–Meier method and compared rates using a stratified log-rank test. We used a
Cox model with adjustment for stratification to calculate hazard ratios. The rate of overall
response was defined as the proportion of patients who had a complete or partial response on
the basis of the IWCLL modified criteria.25 The lymph-node response rate was defined as
the proportion of patients who had a decrease of 50% or more in lymphadenopathy. Overall
survival was defined as the interval from randomization to death from any cause.
All efficacy analyses were based on the intention-to-treat principle unless otherwise stated.
For binary-response end points, we used the Cochran–Mantel–Haenszel chi-square test,
adjusted for stratification, to assess between-group differences. A sequential testing
procedure was applied to adjust for the overall type I error rate — in other words, if the
primary end point was significant, the secondary end points of rates of overall response,
lymph-node response, and overall survival would be tested sequentially. The sample size
provided a power of more than 85% to detect a 75% improvement in the median
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progression-free survival. Two interim analyses were prespecified after approximately 50%
and 75% of the anticipated 119 events had occurred, at alpha levels of 0.001 and 0.005,
respectively.
RESULTS
PATIENTS
The 220 patients who were included in the study were enrolled between May 2012 and
August 2013. The data cutoff for this analysis was August 30, 2013. A total of 78% of the
patients were 65 years of age or older, 40% had at least moderate renal dysfunction
(creatinine clearance, <60 ml per minute), 35% had poor bone marrow function (grade 3 or
higher anemia, thrombocytopenia, or neutropenia), and 85% had a CIRS score of more than
6. The median CIRS score in each study group was 8 (Table 1).
Almost two thirds of the patients had advanced-stage disease, and the median time since the
initial diagnosis of CLL was approximately 9 years. More than 80% of the patients had
unmutated IGHV, and more than 40% had 17p deletion or TP53 mutations. Patients in the
two study groups had received a median of three previous agents, including regimens
containing rituximab, cyclophosphamide, fludarabine, and bendamustine.
A total of 110 patients were randomly assigned to each study group. All 110 patients in the
idelalisib group and 107 in the placebo group actually received the assigned treatment
(Table 1). Of the 3 patients in the placebo group who did not receive study treatment, 2
patients withdrew from the study because of an adverse event and 1 patient had not received
study treatment before the data cutoff.
RECEIPT OF STUDY DRUG
At the time of this analysis, the median time that patients had received a study drug was 3.8
months (interquartile range, 1.9 to 8.6; simple range, 0.3 to 16+) in the idelalisib group and
2.9 months (interquartile range, 1.7 to 5.6; simple range, 0.1 to 14.6) in the placebo group. A
total of 63 patients (39 in the idelalisib group and 24 in the placebo group) received a study
drug for longer than 6 months. The duration of treatment was short for the two study groups
owing to the recommendation of the data and safety monitoring board to stop the study.
However, 81% of patients in the idelalisib group were still receiving the study drug at the
time of study termination, as compared with only 52% in the placebo group. The most
common reason for discontinuation of the study treatment was disease progression.
EFFICACY
Progression-free Survival—At 24 weeks, the rate of progression-free survival was 93%
in the idelalisib group, as compared with 46% in the placebo group (adjusted hazard ratio for
progression or death in the idelalisib group, 0.15; 95% confidence interval [CI], 0.08 to 0.28;
unadjusted P<0.001, which crossed the prespecified stopping boundary for efficacy at the
significance level of 0.001. Disease progression occurred in 12 patients in the idelalisib
group and in 53 patients in the placebo group. The median duration of progression-free
survival among patients in the idelalisib group was not reached, whereas the median
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progression-free survival was 5.5 months in the placebo group (Fig. 1A). The treatment
effect of idelalisib and rituximab was similarly favorable in all prespecified subgroups,
including those stratified according to the presence or absence of the 17p deletion or TP53
mutation and IGHV mutational status (Fig. 2).
Overall Survival—The rate of overall survival in the idelalisib group was superior to that
in the placebo group (92% vs. 80% at 12 months), with an adjusted hazard ratio for death of
0.28 (95% CI, 0.09 to 0.86; P = 0.02). The median duration of overall survival in the two
groups had not yet been reached at the time of analysis (Fig. 1B). Sixteen patients died while
participating in the study: 4 patients (4%) in the idelalisib group and 12 patients (11%) in the
placebo group.
Overall Response—The rate of overall response was evaluated for the 176 patients (88
patients in each study group) who had undergone at least one post-baseline assessment or
had discontinued the study before the first assessment at the time of this analysis. The
overall response rate was 81% (95% CI, 71 to 88) in the idelalisib group, as compared with
13% (95% CI, 6 to 21) in the placebo group (odds ratio, 29.92; P<0.001). All responses were
partial responses.
Lymph-Node Response—A total of 169 patients underwent at least one post-baseline
imaging assessment of the lymph-node response to treatment. On the basis of a review of
imaging results by the independent review committee, the proportion of patients with a
reduction of 50% or more in lymphadenopathy was significantly higher in the idelalisib
group than in the placebo group (93%; 95% CI, 85 to 97; vs. 4%; 95% CI, 1 to 10), for an
odds ratio of 264 (P<0.001) (Fig. 3A).
Idelalisib-Associated Lymphocytosis—Idelalisib, like other novel agents targeting the
B-cell–receptor signaling pathway, has been shown to cause lymphocytosis when it is
administered as a single agent.19 The addition of rituximab to idelalisib blunted and
shortened the duration of the lymphocytosis, which confirmed the findings of a previous
phase 1 study.20 The rate of lymphocytosis peaked at week 2 and resolved by week 12 in the
idelalisib group (Fig. 3B). In contrast, there was a sustained increase in the absolute
lymphocyte count in the placebo group starting at week 24, which coincided with the
completion of rituximab therapy. As per the modified IWCLL guidelines, this rise in the
lymphocyte count was not considered to be disease progression.
ADVERSE EVENTS
Adverse events, serious adverse events, and laboratory abnormalities that occurred during
treatment are listed in Table 2. Most of the adverse events were consistent with those
expected for a population with relapsed CLL that had received extensive prior therapy.
More than 90% of the patients had at least one adverse event. In the idelalisib group, the five
most common adverse events were pyrexia, fatigue, nausea, chills, and diarrhea. In the
placebo group, the adverse events were similar to those in the idelalisib group, with the most
common being infusion-related reactions, fatigue, cough, nausea, and dyspnea. Most adverse
events across the two study groups were grade 2 or lower. In the idelalisib group, grade 3 or
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higher diarrhea was reported in four patients and grade 3 or higher rash was reported in two
patients, with no grade 3 or higher diarrhea or rash reported in the placebo group.
Common laboratory abnormalities included anemia, neutropenia, and thrombocytopenia.
Hepatic aminotransferase elevations occurred more frequently in patients receiving idelalisib
and rituximab than in those receiving placebo and rituximab. Grade 3 or higher elevations
occurred in six patients (5%) in the idelalisib group, with onset at 8 to 16 weeks. The study
drug was with-held and successfully reinitiated in four of these six patients. No patients
discontinued the study drug because of aminotransferase elevations.
At least one serious adverse event occurred in 44 patients (40%) in the idelalisib group and
in 37 patients (35%) in the placebo group. The most frequent serious adverse events in the
two groups were pneumonia, pyrexia, and febrile neutropenia.
Adverse events leading to study-drug discontinuation were reported in 9 patients (8%) in the
idelalisib group and 11 patients (10%) in the pla cebo group. In the idelalisib group,
gastrointestinal and skin disorders contributed to 6 discontinuations. In the placebo group,
infections and respiratory disorders contributed to 8 discontinuations.
DISCUSSION
In our study involving patients with relapsed CLL who were not able to undergo standard
cytotoxic chemotherapy, treatment with idelalisib and ri tuximab was associated with
significant improvement in the rate of progression-free survival, as compared with placebo
and rituximab, a finding that warranted termination of the study after the first prespecified
interim analysis. We chose rituximab monotherapy as the comparator for this study on the
basis of National Comprehensive Cancer Network guidelines and clinical-use data showing
that the drug is a commonly prescribed treatment in the United States for this population and
is increasingly being prescribed in Europe (see the Supplementary Appendix, available at
NEJM.org). The patients were defined as less able to receive cytotoxic chemotherapy on the
basis of severe myelosuppression from previous chemotherapy, reduced kidney function, or
a CIRS score of more than 6 for non–CLL- related coexisting illnesses. We used a schedule
for the administration of rituximab that was approved in combination with fludarabine and
cyclophosphamide; two additional doses were added to achieve dose intensification.
Improvement in progression-free survival was observed not only in the overall study
population but also in all subgroups examined, including patients with poor prognostic
features, such as 17p deletion or TP53 mutations and unmutated IGHV. The rate of
progression-free survival in the placebo group was similar to that reported for rituximab
monotherapy in other trials involving patients who were not selected on the basis of medical
fitness for chemotherapy. Furthermore, the median duration of progression-free survival
among patients receiving placebo and rituximab was similar to the range of 5.7 to 5.9
months reported among patients receiving monotherapy with ofatumumab, another anti-
CD20 antibody approved as monotherapy for disease that is resistant to fludarabine and
alemtuzumab.28 In addition, patients receiving idelalisib and rituximab had significant
improvement in overall survival, as compared with those receiving placebo and rituximab.
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This improvement in survival is further evidence of the clinical importance of the
progression-free survival benefit shown in this trial. Significant differences favoring the
idelalisib group were also observed in rates of overall response and lymph-node response.
There was no overall increase in the rate of adverse events with the addition of idelalisib to
rituximab, as compared with placebo and rituximab. Grade 3 or 4 adverse events were
common in the two study groups, which was an expected finding, given the large number of
previous treatments, clinically significant coexisting illnesses, and prolonged time since the
initial diagnosis of CLL in these patients. In earlier studies, idelalisib was associated with
elevated aminotransferase elevations, rash, and severe diarrhea.19 These adverse events were
reported in the idelalisib group in our study as well, albeit at a low frequency, and severe
events were generally managed with study-drug interruption and symptom treatment. Since
the study was stopped early for efficacy, severe diarrhea, which is typically a late-onset
event, may yet occur in some patients. A surprising finding was a reduction in rates of
infusion-related toxicity from rituximab in the idelalisib group.
In conclusion, the addition of idelalisib to rituximab in a population of frail, difficult-to-treat
patients, including those with adverse genetic features such as 17p deletion or TP53
mutations or unmutated IGHV, was superior to rituximab monotherapy, which is commonly
used in such patients. Although the follow-up in this study was short, combination therapy
with idelalisib had an acceptable safety profile. Further follow-up is needed to assess
whether idelalisib is safe for long-term use. Patients with CLL who are less able to undergo
standard chemotherapy are frequently excluded from clinical trials because of the presence
of coexisting illnesses, yet such patients are often seen in clinical practice. On the basis of
response rates and progression-free survival results, the combination of idelalisib and
rituximab may be a treatment option for these patients. Idelalisib is part of a growing list of
agents with activity in CLL, including ibrutinib (targeting Bruton's tyrosine kinase)29 and
ABT-199 (targeting B-cell lymphoma 2 protein [BCL2]).30 Additional studies will be
necessary to define the most effective use of these new agents.
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Figure 1. Progression-free and Overall Survival
At the time the study was stopped, the median duration of progression-free survival among
110 patients receiving idelalisib and rituximab had not yet been reached; among the 110
patients receiving placebo and rituximab, the median duration of progression-free survival
was 5.5 months (hazard ratio for progression or death in the idelalisib group, 0.15; 95%
confidence interval [CI], 0.08 to 0.28; P<0.001) (Panel A). The median duration of overall
survival in the two study groups had also not been reached; the overall survival rate was
92% in the idelalisib group versus 80% in the placebo group at 12 months (hazard ratio for
death, 0.28; 95% CI, 0.09 to 0.86; P = 0.02) (Panel B).
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Figure 2. Forest Plot of Progression-free Survival in Prespecified Subgroups
Hazard ratios of less than 1.00 for disease progression or death indicate better results in the
idelalisib group.
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Figure 3. Changes in Lymph Nodes and Lymphocytes
Shown are the greatest percentage changes in the sum of the products of the perpendicular
diameters of measured lymph nodes for each study patient (Panel A) and the median
absolute lymphocyte counts over a period of 48 weeks (Panel B). The I bars represent
interquartile ranges.
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Table 1
Characteristics of the Patients at Baseline and Study Status.*
Characteristic Idelalisib plus Rituximab (N = 110) Placebo plus Rituximab (N = 110)
Median age (range) – yr 71 (48-90) 71 (47-92)
Rai stage – % of patients†
    0 0 1
    1 or 2 31 26
    3 or 4 64 65
    Missing data 5 7
Extent of CLL – % of patients
    Anemia
        Any grade 75 72
        Grade ≥3 6 11
    Neutropenia
        Any grade 34 35
        Grade ≥3 17 16
    Thrombocytopenia
        Any grade 62 61
        Grade ≥3 16 29
Median absolute lymphocyte count (range) – per mm3 31,960 (280-262,710) 30,880 (290-398,740)
Median estimated creatinine clearance (range) – ml/min 62 (32-161) 67 (23-199)
Genetic stratification factors – % of patients
    Unmutated IGHV 83 85
    17p Deletion or TP53 mutation 42 45
Median CIRS score (range)‡ 8 (3-18) 8 (1-18)
Previous CLL treatment
    Median no. of drugs (range) 3 (1-12) 3 (1-9)
    Drugs – % of patients
        Rituximab 91 88
        Cyclophosphamide 64 70
        Fludarabine 56 64
        Bendamustine 58 54
        Chlorambucil 31 22
Study status – %
    Underwent randomization 100 100
    Continued participation in the study 81 52
    Discontinued participation in the study 19 48
        Disease progression 5 31
        Death§ 3 8
        Adverse events 5 5
        Physician's decision 1 1
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Characteristic Idelalisib plus Rituximab (N = 110) Placebo plus Rituximab (N = 110)
        Patient's decision 5 3
        Other 1 0
*
There were no significant differences between the two groups at baseline. Percentages may not total the overall number in the category because of
rounding. CLL denotes chronic lymphocytic leukemia.
†
In the Rai staging system, stage 0 denotes low-risk disease, stage 1 or 2 intermediate risk, and stage 3 or 4 high risk.
‡Scores on the Cumulative Illness Rating Scale (CIRS) range from 0 to 56, with higher scores indicating an increased number or severity of
coexisting illnesses.
§
The listed deaths do not include one in the idelalisib group and four in the placebo group that occurred after the patients withdrew from the study
because of an adverse event or disease progression.
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Table 2
Adverse Events, Serious Adverse Events, and Key Laboratory Abnormalities.*
Event Idelalisib plus Rituximab (N = 110) Placebo plus Rituximab (N = 107)
Any Grade Grade ≥3 Any Grade Grade ≥3
number (percent)
Adverse event during treatment 100 (91) 62 (56) 101 (94) 51 (48)
    Pyrexia 32 (29) 3 (3) 17 (16) 1 (1)
    Fatigue 26 (24) 3 (3) 29 (27) 2 (2)
    Nausea 26 (24) 0 23 (21) 0
    Chills 24 (22) 2 (2) 17 (16) 0
    Diarrhea 21 (19) 4 (4) 15 (14) 0
    Infusion-related reaction 17(15) 0 30 (28) 4 (4)
    Cough 16 (15) 0 27 (25) 2 (2)
    Constipation 13 (12) 0 12 (11) 0
    Decreased appetite 13 (12) 0 9 (8) 1 (1)
    Vomiting 13 (12) 0 8 (7) 0
    Dyspnea 12 (11) 2 (2) 20 (19) 3 (3)
    Night sweats 11 (10) 0 8 (7) 0
    Rash 11 (10) 2 (2) 6 (6) 0
Serious adverse event 44 (40) NA 37 (35) NA
    Pneumonia 7 (6) NA 9 (8) NA
    Pyrexia 7 (6) NA 3 (3) NA
    Febrile neutropenia 5 (5) NA 6 (6) NA
    Sepsis 4 (4) NA 3 (3) NA
    Pneumonitis 4 (4) NA 1 (1) NA
    Diarrhea 3 (3) NA 1 (1) NA
    Neutropenia 3 (3) NA 1 (1) NA
    Pneumocystis jirovecii pneumonia 3 (3) NA 1 (1) NA
    Neutropenic sepsis 3 (3) NA 0 NA
    Dyspnea 1 (1) NA 4 (4) NA
    Cellulitis 1 (1) NA 3 (3) NA
Laboratory abnormality
    ALT or AST elevation 38 (35) 6 (5) 20 (19) 1 (1)
    Anemia 28 (25) 6 (5) 32 (30) 15 (14)
    Neutropenia 60 (55) 37 (34) 52 (49) 24 (22)
    Thrombocytopenia 19 (17) 11 (10) 28 (26) 17 (16)
*
Listed are all adverse events that were reported in at least 10% of patients and all serious adverse events that were reported in at least three
patients in at least one of the study groups. Patients with more than one occurrence of the same type of adverse event or serious adverse event are
listed only once. ALT denotes alanine aminotransferase, AST aspartate aminotransferase, and NA not applicable (because serious adverse events
are reported as severe regardless of the severity grading).
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